1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Multiple due dates: Jun 22, 2026; Feb 20, 2027; Jun 22, 2027
Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). This funding opportunity supports the development of biomarkers or clinical outcomes from digital health technology for remote monitoring in clinical trials.
Get alerted about grants like this
Save a search for “National Cancer Institute (NCI), National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional) Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93. 866 -- Aging Research 93.
853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders Last Updated: May 13, 2026 View version history on Grants. gov The purpose of this proposed Notice of Funding Announcement (NOFO) is to support development of biomarkers or clinical outcomes derived from digital health technology (DHT) for use in clinical trials for remote monitoring as primary or secondary endpoints.
To improve clinical impact, increase statistical feasibility, and promote standardization, applicants will be expected to develop and test the digitally derived assessments in populations from at least three different diseases or conditions. Partnerships with non-profit patient advocacy organizations will be required.
Nonprofits non-higher education without 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) For-profit organizations other than small businesses Public and Indian housing authorities City or township governments Special district governments Federally recognized Native American tribal governments Independent school districts Public and state institutions of higher education Private institutions of higher education Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Grantor contact information See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
File name Description Last updated PAR-25-170-Full-Announcement. html PAR-25-170 Full Announcement Text Nov 13, 2024 03:21 PM UTC Link to additional information https://grants. nih.
gov/grants/guide/pa-files/PAR-25-170. html Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
Based on current listing details, eligibility includes: EGRP joins with other NCI Divisions, Offices, and Centers and other Institutes and Centers at the National Institutes of Health (NIH) to fund grant applications. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Project-specific Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is June 23, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). This funding opportunity invites investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically GLP-1 or dual GLP-1/GIP-1 receptor agonists, impact cancer risk. The focus includes reported effects on thyroid, prostate, and other cancer risks. The NOFO also aims to attract scientists from other fields to study incretin mimetic effects on cancer biology.
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01, Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). This funding opportunity supports the validation of assays developed from existing NIH R01 projects to accelerate their clinical use. This could include mass spectrometry-based assays for secreted protein biomarkers that have shown promise in earlier research.